TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Post-licensure Safety Study of IMOJEV® in Thailand

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children requiring vaccination against Japanese encephalitis~* Children aged 9 months to less than 5 years on the day of inclusion~* In good general health at the time of inclusion~* Informed consent form has been signed and dated by the parent(s)/legal guardian(s)~* Subject and parent(s)/legal guardian(s) are able to attend the scheduled visit and any additional visits that may need to be done in case of an SAE (including AESI), and are able to comply with all trial procedures~* The subject's parent(s)/legal guardian(s) have a telephone number at which they can be contacted throughout the study~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the vaccination~* Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination~* Planned participation in another clinical trial during the present trial period~* Children previously vaccinated with the live attenuated Japanese encephalitis vaccine CD-JEVAX® (SA14-14-2 LAV)~* Contraindications to vaccination according to the IMOJEV® Summary of Product Characteristics (SmPC)~* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study~* Children who received IMOJEV® as primary vaccination in this study.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- Primary Vaccination Group (Type: EXPERIMENTAL): Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
- Booster Vaccination Group (Type: ACTIVE_COMPARATOR): Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Resistance in Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On aspirin 81-325mg daily at time of enrollment~* Documented stable coronary artery disease or \> 6 months after coronary artery bypass grafting or interventional cardiac procedure~* Written informed consent~Exclusion Criteria:~* Pre-menopausal female~* Renal disease (creatinine \>= 2 mg/dl)~* Anemia (Hematocrit \< 30%)~* Thrombocytopenia (platelet count \< 135,000/ul)~* Use of NSAIDs or coxibs within the previous 2 weeks~* Concurrent use of other anti-platelet agents~* Uncontrolled hypertension (systolic BP \> 180 mmHg)~* Decompensated congestive heart failure~* Recent coronary syndrome (\< 6 months)~* History of significant GI bleeding

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enteric-coated aspirin (Type: EXPERIMENTAL): patients received enteric-coated aspirin 81 mg qd for 2 weeks
- Chewable aspirin (Type: ACTIVE_COMPARATOR): Patients received chewable aspirin 81 mg qd for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Osteopathic Manipulative Therapy in Nonsynostotic Plagiocephaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants with NSP, ODDI score of 104% or more.~* To be at term corrected age if born prematurely.~Exclusion Criteria:~* Synostotic Plagiocephaly~* Infant who underwent an osteopathic manipulative treatment before the enrolment~* Dysmorphisms~* Syndromes~* Congenital Muscular Torcicolis~* Cerebral Palsy

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Osteopathic manipulative therapy (Type: EXPERIMENTAL): Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits.
- Light Touch Therapy (Type: SHAM_COMPARATOR): Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- History of at least 1 HAE attack per month or any history of laryngeal edema~In addition, this study was open to all subjects who:~* Completed participation in LEVP2005-1/B (NCT01005888) any time after the final prophylactic therapy in Part B~* Were enrolled but not randomized in LEVP2005-1/A (NCT00289211) after Part A was closed~* Were enrolled and randomized in LEVP2005-1/A after LEVP2005-1/B was closed to enrollment, any time after the 3-day telephone follow-up~* Were excluded from LEVP2005-1 for any of the following reasons:~  * Pregnancy or lactation~ * Age less than 6 years~ * Narcotic addiction~ * Presence of anti-C1 inhibitor (C1INH) autoantibodies~* Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances:~  * Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or~ * Had a known HAE-causing C1INH mutation, or~ * Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator~Exclusion Criteria:~* History of allergic reaction to C1INH or other blood products~* Participated in any other investigational drug study within the past 30 days other than those sponsored by Lev Pharmaceuticals~* Received blood or a blood product in the past 60 days other than C1INH-nf

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label C1INH-nf (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 18 to 60 years~* Patients with ARVI, including influenza, starting not later than for 1 day prior to inclusion in the study:~* The body temperature measured axillary above 37.2 °C~* Presence of one of the signs of respiratory disease (runny nose, cough, pain / tickling in the throat)~* Presence of one of the systemic symptoms (weakness, myalgia, headache , chills, sweating)~* Provide written informed consent~* Ability to understand the nature of the study and provide written informed consent in accordance with Good Clinical Practice (GCP) and local law~Exclusion Criteria:~* Age over 60 years and under 18 years old~* Presence of allergic reactions~* Intolerance to NSAIDs and iodine-containing drugs~* Hypersensitivity to the components of the drug~* Mental illness that impedes compliance with the research procedure~* Pregnancy or breast-feeding~* Presence of acute, clinically significant respiratory and cardio vascular insufficiency, functional disorders of liver, kidney, digestive tract (ulcer disease) determined at physical examination or by laboratory screening tests~* Presence of congenital defects or serious chronic disease of the lungs, kidneys, cardiovascular system, nervous system, metabolic disorders, psychiatric disorders, confirmed by patients history or during initial examination~* The use of preparations of blood cytokine immunoglobulin in for 3 months prior to the study~* Chronic use of alcohol and / or drugs~* Presence or history of cancer diseases, HIV, hepatitis B and C~* Application of immunosuppressive or immunomodulatory drugs for 6-months prior to the study~* Women of child-bearing potential and who do not use acceptable measure of contraception or do not plan to use those throughout the study~* Any clinical condition that, according to the investigator, will not allow to safely carry out the protocol and take the studied drugs without risk to health~* Patients receiving antiviral therapy,~* Participation in other clinical trials at the present time or during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - Active Treatment (Type: EXPERIMENTAL): Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
- Group 2 - Placebo (Type: PLACEBO_COMPARATOR): Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Males and females 18 years to 40 years of age (inclusive).~2. Outpatients who have undergone surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction.~3. Subject must have at least moderate pain on the 4 point categorical scale, confirmed by at least 50 mm on the 100 mm VAS PSR scale within approximately 5 hours (ie, less than or equal to 5 hours, 15 minutes) after surgery is completed.~4. In general good health and have no contraindications to the study or rescue medication.~Exclusion Criteria~1. Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Investigator to place the subject at increased risk, including the presence or history within 2 years of screening of the following medical conditions/disorders:~   * Gastrointestinal ulcer or gastrointestinal bleeding;~  * Paralytic ileus or other gastrointestinal obstructive disorders;~  * Bleeding disorder.~2. Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID; or to APAP, tramadol, other opioids, or to their combinations.~3. Prior use of any type of analgesic or NSAID within five half lives of that drug or less before taking the first dose of investigational product, except for pre anesthetic medication and anesthesia for the procedure.~   .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg (Type: ACTIVE_COMPARATOR): FDC IBU/APAP 250 mg/500 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 or older and sign written informed consent.~* Must be wiling and able to comply with protocol.~* Must have active seborrheic dermatitis of the face.~Exclusion Criteria:~* No history of overt bacterial, viral or fungal infection of the head/neck.~* No history or presence of compromising dermatosis elsewhere on the skin~* No Parkinson's disease, HIV, infections or disorders of the central nervous system~* No actinically damaged skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Elidel Cream (pimecrolimus) (Type: EXPERIMENTAL): Elidel Cream to be applied twice daily for 4 weeks
- Ketoconazole Cream (Nizoral) (Type: ACTIVE_COMPARATOR): Ketoconazole Cream to be applied twice daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent~Exclusion Criteria:~* Subjects with a previous or suspected disease caused by N. meningitidis~* previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* previous or suspected disease caused by N. meningitidis~* Any serious acute, chronic or progressive disease~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Licensed Meningococcal Vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
- Novartis MenACWY Conjugate Vaccine (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: InSite for Over Active Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of OAB including urinary urge incontinence or urgency-frequency~* Be male or female at least 18 years of age or older~* Be able to consent to participate by signing the Informed Consent~* Be willing and able to attend visits and comply with the study protocol including adequate operation of equipment~* Have failed or are not a candidate for more conservative treatment (e.g. pelvic floor training, biofeedback, behavioral modification)~* Have failed or could not tolerate (stopped taking medication due to lack of efficacy or intolerable side effects) at least one anticholinergic or antimuscarinic medication AND have at least one anticholinergic or antimuscarinic medication not yet attempted~* Have been on current regiment of OAB medications or have not been on any OAB medications, for at least 4 weeks prior to beginning the baseline voiding diary~Exclusion Criteria:~* Have severe or uncontrolled diabetes or diabetes with peripheral nerve involvement~* Have concomitant medical conditions which would limit the success of the study procedure~* Have skin, orthopedic or neurologic anatomical limitations that could prevent successful placement of an electrode~* Have neurological diseases such as multiple sclerosis, clinically significant peripheral neuropathy or complete spinal cord injury (e.g., paraplegia)~* Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or RF energy exposure~* Have urinary tract mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture~* Have symptomatic urinary tract infection (UTI)~* Have implantable neurostimulators, pacemakers, or defibrillators~* Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component~* Have had treatment of urinary symptoms with botulinum toxin therapy in the past 12 months~* Be a woman who is pregnant or planning to become pregnant or are a woman of child-bearing potential who is not using a medically-acceptable method of birth control~* Have a life expectancy of less than one year~* Have plans to enroll in another investigation device or drug trial during their participation in this trial, or currently enrolled in an investigational device or drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): InterStim Therapy
- 2 (Type: ACTIVE_COMPARATOR): Standard Medical Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCE With FMT in the Treatment of Childhood Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* 4-14 years old;~* Roman IV criteria for childhood constipation;~* After a course of PEG and a course of Chinese medicine treatment was ineffective;~* Barium enema showing fecal impaction.~Exclusion criteria:~* Congenital and/or acquired intestinal diseases, such as congenital megacolon, intestinal stenosis, polyps, Crohn's disease, tuberculosis, inflammation, and tumors;~* Anorectal diseases, such as anal atresia, fistula, abscess, and tumor;~* Neurological diseases, such as brain and spinal cord diseases;~* genetic metabolic diseases;~* psychosocial and behavioral diseases;~* other systemic diseases;~* Refused to participate in.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Fecal supernatant (Type: ACTIVE_COMPARATOR): Fecal supernatant is used for treatment of childhood Constipation
- non-Fecal supernatant (Type: PLACEBO_COMPARATOR): Placebo is used for treatment of childhood Constipation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed type 2 diabetes~* Age: 50-79 years old~* LDL-cholesterol more than 2.9 mmol/l~Exclusion Criteria:~* Current or previous (within 6 months) use of estrogen therapy~* Cancer~* Chronic gastrointestinal diseases~* Current use of antibiotics~* Any severe liver or renal diseases~* Systolic blood pressure more than 180 mmHg or phase 3 hypertension~* Any severe mental diseases~* Severe cardio- or cerebro-vascular diseases

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis Versus On-demand Therapy Through Economic Report

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 12 years and ≤ 55 years~* severe haemophilia A (FVIII \< 1%)~* absence of inhibitors (Bethesda titre \< 0.6 BU/ml)~* Previous Treated Patients (prior exposure days \> 200)~* Kogenate Bayer administered 20-30 IU/kg -3 times a week, for the prophylaxis group~* ≥ 6 joint bleeds requiring treatment with FVIII concentrates in the previous 6 months before enrollment, for on-demand group~* written informed consent~Exclusion Criteria:~* concomitant severe and chronic diseases or congenital skeletal malformation~* unreliability of patient or likelihood of follow-up failure~* presence of inhibitors or history of inhibitors (in the previous 2 years)~* currently on immune tolerance treatment~* hepatic cirrhosis or liver disease in rapid progression~* AIDS~* platelet count \< 75,000/mm3~* presence of conditions that influence negatively patient´s compliance~* participation in another study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None
- Group 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Nano-silver Fluoride and Silver Diamine Fluoride for Arresting Early Childhood Caries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children younger than 4 years old.~* The presence of at least one active carious lesion on a primary tooth, with scores 3 and higher (according to the International Detection and Assessment System- ICDAS II)~* Completion of an informed consent to participate in the study.~Exclusion Criteria:~* Children reporting spontaneous or elicited pain from caries or showing any signs of pulpal infection, swelling and/or abscess, obvious discoloration of the tooth and premature hypermobility.~  * Parental refusal to participate in the study.~ * Allergy or sensitivity to silver or any of the materials included in the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: EXPERIMENTAL): None
- group 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete